PMC:7795856 / 14971-15851
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
269 | 156-163 | Gene | denotes | insulin | Gene:3630 |
270 | 286-289 | Gene | denotes | Tα1 | Gene:134864 |
271 | 843-846 | Gene | denotes | Tα1 | Gene:134864 |
272 | 466-469 | Chemical | denotes | PAS | |
273 | 523-527 | Chemical | denotes | RimJ |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T92 | 0-426 | Sentence | denotes | Of note, in contrast to classical approaches, which involve the use of an insoluble fusion partner, for example, an α-galactosidase fragment in the case of insulin [43], to provoke formation of inclusion bodies and protect the gene product from intracellular proteolysis, the PASylated Tα1 peptide was recovered as a soluble fusion protein, thus allowing direct purification from the cell extract without solubilization steps. |
T93 | 427-551 | Sentence | denotes | Furthermore, the C-terminally attached PAS moiety was compatible with N-terminal acetylation by RimJ as confirmed by ESI-MS. |
T94 | 552-880 | Sentence | denotes | Yields of our expression study at the research scale reached 15 mg purified acetylated Tα1-PAS and even 50 mg PAS-Tα1 per 1 L bacterial culture (at an optical density (OD) of 3), which surpasses the reported yield of a bacterially produced (yet probably non-acetylated and non-glycosylated) Tα1-Fc fusion protein (16 mg/L) [44]. |